KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
about
Current targeted therapies in the treatment of advanced colorectal cancer: a reviewPersonalized treatment for advanced colorectal cancer: KRAS and beyondEpigenetics advancing personalized nanomedicine in cancer therapyKRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapyEGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinomaA comparability study of 5 commercial KRAS testsFuture of personalized medicine in oncology: a systems biology approach.PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinomaCost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancerKRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies.The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare.KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancerReliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.Personalized medicine and cancer.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.KRAS mutation testing in metastatic colorectal cancerMultiple-to-multiple relationships between microRNAs and target genes in gastric cancerTargeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencingCost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer.Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancerCanadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Association between KRAS mutation and lung metastasis in advanced colorectal cancer.C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer.Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.
P2860
Q26740067-584414FB-D507-46E5-9214-CB8940E3A182Q26822817-734DB42E-DA03-431B-823D-1E1028C354FCQ27010637-DFA1AA92-DD10-4E49-A4E3-CD72B1B868FBQ27851532-85C08A75-2224-46C3-ADB2-587ABAADCB4DQ27853338-3886C089-B5BE-49CF-A9B5-4C5E22D7E9FAQ28258483-FC2279AD-41BA-45A7-BC39-42DE3E876420Q28476652-EBF3E2ED-EC25-49B6-BE1B-8F54501E56A4Q28538710-90A847A0-98C3-4069-A52B-74B53206D168Q33402525-34396F64-2B35-4F1F-8B15-A98B65316904Q33514878-AB0DAF5F-5700-407A-8677-A61D9A403419Q33620070-C148D010-21EC-4A7F-B60E-90165B4EADAEQ33727871-AE7AC7DC-666F-4C0A-A7FB-F157CF22870AQ33813835-0A372839-2E10-40EB-B2C0-9DABE402AA88Q33888034-E9EA8FE6-51BC-462D-B5F5-603D1889D7B5Q33898189-D597B755-B3DD-44CA-B206-0230717E9464Q33939881-04D22B94-5973-4D2A-9D3A-5CA36B092BA3Q33943630-1EB9C364-9E7E-4042-A11A-7E51BCB07EF5Q33982704-93044F2F-2EEB-4993-89FB-7A5B9143061DQ33983671-F8EBB32B-4F05-4603-A34B-5BDDF5077982Q34084873-6E8ACAD9-43D8-4DE6-A617-DDC8A63991D3Q34095970-43E0E9BE-2A45-40F8-81EB-67BB64452BF4Q34142761-83AF5B9D-0E25-4CD8-9DE3-406DC2F5624DQ34192568-30A9140A-ED17-4D4A-8DF1-70285E067CF5Q34245784-6C8C9CBF-A0F5-407E-B9D9-041C72768E47Q34608577-6A58B1DB-642A-4B36-9DB0-7E320CCFBCF8Q34632966-625E4FBD-810E-4CEF-858D-AF5FC03D3658Q34643960-F9D864E2-BE62-4C92-94D7-DECF68866CD1Q34717401-2C7BF886-E7C7-436F-B471-4B11C969375DQ34735416-558E8E44-B5EC-4F5E-BCC4-F7D0DD8FDF8CQ34960017-49F32D1A-9CE5-409B-B110-16F237D6886AQ35009672-3DFB0AFE-94B5-4B29-8902-CD8E595BEE3FQ35013457-F90AC964-35F5-4DA2-BA26-E043BD24C136Q35076220-6FD8EF08-9CD3-41B3-8128-0822669C3167Q35145683-D8DC037A-D8BD-4250-BDE1-B9D168917713Q35212649-46F69EF6-717C-47AC-B22E-C6D8A88608A5Q35233751-AA495018-0C9E-4969-8926-626BCA02512AQ35584153-E7B130B9-0A36-4665-8B11-5AE01CD7FBD2Q35677827-2CC63355-92FE-4968-B60E-9FB19ADC268DQ35677900-01976AD2-39DD-47DD-B9F9-A4EF10270E21Q35817101-CC249FE9-B121-4D47-B154-59F0AC6023BE
P2860
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
KRAS mutations and sensitivity ...... lication of patient selection.
@en
KRAS mutations and sensitivity ...... lication of patient selection.
@nl
type
label
KRAS mutations and sensitivity ...... lication of patient selection.
@en
KRAS mutations and sensitivity ...... lication of patient selection.
@nl
prefLabel
KRAS mutations and sensitivity ...... lication of patient selection.
@en
KRAS mutations and sensitivity ...... lication of patient selection.
@nl
P2093
P356
P1476
KRAS mutations and sensitivity ...... lication of patient selection.
@en
P2093
Antonio Jimeno
Fred R Hirsch
S Gail Eckhardt
Wells A Messersmith
Wilbur A Franklin
P304
P356
10.1200/JCO.2008.19.8168
P407
P577
2009-01-05T00:00:00Z